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Ovarian cancer is the fifth most deadly cancer among women and the deadliest 
gynecologic cancer in the United States. Although it is a relatively rare form of cancer, 
its toll on morbidity and mortality is not equally distributed. In Maryland, women who 
reside at distance extremes (< 10 miles and > 50 miles) to an urban NCI-designated 
cancer center (NCI-CC) are less likely to complete treatment for gynecologic 
malignancies. In California, women with low socioeconomic status and those who live 
more than 50 miles from an NCI-CC are less likely to receive guideline-adherent care 
and have worse ovarian cancer survival. Our objective was to examine the impact of 
residential distance and socioeconomic status on survival outcomes for patients 
receiving treatment for ovarian cancer at a frontier-state NCI-CC. 
Patients who were treated for ovarian cancer at a single institution from 2010-2015 were 
identified. Age at diagnosis, insurance status, and distance from the patient’s home to 
the institution were abstracted. Median income was estimated using 2013 American 
Census Survey. Clinical data including stage at diagnosis, surgical status, 
chemotherapy cycles, Charlson comorbidity index, dates of diagnosis, recurrence, and 
death were obtained. Patients treated at other institutions and those with non-epithelial 
pathology were excluded. Overall survival (OS) and progression free survival (PFS) 
were analyzed by Kaplan Meier survival curves and cox proportional hazard models 
using SAS v9.4. 
A total of 329 patients were identified, 227 patients completed all care at the institution 
and 102 patients completed partial care. Among patients who received all their care at 
the NCI-CC, survival analysis based on distance demonstrated that patients who lived 
less than 10 miles from the institution had worse survival (p=0.0137). 5-year survival 
was 37% for patients who lived less than 10 miles from the institution and 57% for those 
who lived greater than 10 miles away. Lower median income (<$55,268) regardless of 
distance to institution was also associated with worse survival, p = 0.0210. Among 
patients who received partial care at the institution, greater than 80% received NCCN 
guideline adherent care. There was no survival disparity between patients who received 
all vs partial care at our NCI-CC.   
Among patients who received all care for ovarian cancer at our institution, stage at 
diagnosis, presence of comorbidities, lower median income and residential distance 
less than 10 was associated with worse overall survival. We report high rates of NCCN 
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Ovarian cancer is the most lethal gynecologic cancer in the United States (US).  In 2020, 
it is estimated that there will be 21,750 new cases of ovarian cancer and 13,940 ovarian 
cancer deaths [1]. Although, ovarian cancer comprises 2.5% of all cancers diagnosed in 
women, it is responsible for 5% of female deaths attributed to cancer, making it the fifth 
leading cause of cancer death in the US [2]. Outcomes from this deadly cancer are not 
equal across racial/ethnic groups or geographic populations. African American/non-
Hispanic Black (NHB) women have the second highest mortality rates (6.6 deaths per 
100,000 women) despite relatively low incidence rates (9.4 per 100,000) [2]. 
Caucasian/non-Hispanic White (NHW) women have the highest rate of ovarian cancer 
incidence (12.0 per 100,000) and mortality (7.9 deaths per 100,000) [2]. Lower rates of 
survival in NHB women can be attributed in part to late stage of diagnosis, a lower 
likelihood of receiving optimal treatment, and the presence of more comorbidities 
compared with other women [2-7]. National Comprehensive Cancer Network (NCCN) 
guideline non-adherent care is an independent predictor of inferior overall survival [6]. 
Median income less than $35,000 is also negatively associated with survival [6]. The three 
strongest predictors of poor survival outcomes after controlling for non-NCCN guideline 
adherent care, are NHB race, Medicaid payer status and non-insured status; each 
accounting for a 30% increased risk of death [6]. 
Geographic disparities in ovarian cancer survival also exist but are not as well studied as 
racial/ethnic disparities. A recent study has shown that women who reside in the southern 
US have worse outcomes regardless of race [8]. In California, receipt of NCCN guideline 
adherent care was independently associated with geographic proximity to a high-volume 
hospital[9]. NHB race, low socioeconomic status, and geographic location ≥ 50 mi from a 
3 
 
high-volume hospital were independently associated with an increased risk of non-
adherent care [9]. Geographic distance from treatment facility has been shown to 
contribute to disparities in completion of gynecologic cancer treatment [10]. This smaller 
study (n= 150) at an urban NCI-designated cancer center (NCI-CC) in Baltimore, 
determined that distance extremes (<10 miles and >50 miles), increased travel time and 
medical comorbidities were associated with a lower likelihood of treatment completion for 
gynecologic malignancies [10].  
The primary objective of this study is to determine if geographic distance from a single 
NCI-CC, with a large catchment area that spans the entire state of Kansas and western 
Missouri, is associated with differences in survival. The secondary objective is to 
determine rates of NCCN guideline adherent care among patients who received partial 











Racial disparities in ovarian cancer survival has long been established. The largest 
study to date, used findings from the CONCORD-2 study and covered 80% of the US 
population [11]. To analyze ovarian cancer survival by state and race between 2001-
2009, data from the Center for Disease Control and Prevention’s National Program of 
Cancer Registries (NPCR) and National Cancer Institutes’ Surveillance, Epidemiology 
and End Results (SEER) Program were used [11]. This study found that ovarian cancer 
survival was worse for NHB women and did not improve over time in most of the 37 states 
included [11]. Of the 172,849 women included in this population-based study, none were 
from the state of Kansas.   
Another study completed by Bristow et al used a population-based analysis of National 
Cancer Data Base (NCDB) records for primary ovarian cancer diagnosed between 1998 
to 2002 [6]. Main outcome measures were differences in adherence to NCCN guidelines 
and overall survival by race and socioeconomic status. Non-NCCN guideline adherent 
care was an independent predictor of inferior overall survival. Median income less than 
$35,000 was also negatively associated with survival [6]. The three strongest predictors 
of poor survival outcomes after controlling for non-NCCN guideline adherent care, were 
NHB race, Medicaid payer status and non-insured status; each accounting for a 30% 
increased risk of death [6]. Although this study used a large validated database of over 
45,000 patients, information including the specifics of surgical outcome (i.e. residual 
disease - a predictor of survival), type of number of chemotherapy cycles administered 
and medical comorbidities were not available. Our proposed research involves patients 
treated solely at our cancer center; thus, we have access to their entire treatment history 
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allowing us to better account for differences in surgical outcome, chemotherapy and 
medical comorbidities.  
Geographic disparities in ovarian cancer survival also exist but are not as well 
studied as racial/ethnic disparities. A recent study has also shown that women who 
reside in the southern US have worse outcomes regardless of race [8]. In California, 
receipt of NCCN guidelines adherent care was independently associated with geographic 
proximity to a high-volume hospital [9]. In this large study of over 11,000 patients 
diagnosed from 1996-2006, only 45.5% received NCCN guideline adherent care. NHB 
race, low socioeconomic status, and geographic location ≥ 50 mi from a high-volume 
hospital were independently associated with an increased risk of non-adherent care [9]. 
Although this study used the validated California Cancer Registry, medical comorbidity 
information was not available and the census block of residence for each subject was 
used rather than exact residence due to de-identification. Additionally, the California 
Cancer Registry did not capture physician volume or physician specialty. These potential 
confounders are not be present in our study because we have access to the identified 
information of all patients in the study and the specialties of treating physicians. 
Geographic distance from treatment facility has been shown to contribute to disparities in 
completion of gynecologic cancer treatment [10]. In this smaller study (n = 150) describing 
incident gynecologic cancer diagnoses between 2009-2011 at an urban NCI-designated 
cancer center (NCI-CC) in Baltimore, distance extremes (<10 miles and >50 miles), 
increased travel time and medical comorbidities were associated with a lower likelihood 
of treatment completion for gynecologic malignancies [10]. This study was of all 
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gynecologic cancers, not specifically ovarian cancer and did not examine survival 
outcomes.  
 
NHB women and those who live farther away from an NCI-CC have been shown to have 
worse ovarian cancer outcomes. Social determinants of health, including community and 
social contextual factors have also been shown to affect cancer outcomes. A secondary 
analysis of data from an ovarian cancer clinical trial sought to correlate health-related 
quality of life with social determinants of health [12]. This study of over 900 patients found 
no correlation between race, distance traveled and community socioeconomic status to 
physical well-being, functional well-being, ovarian-specific well-being, and trial outcome 
index [12]. However, higher health-related quality of life was associated with private 
insurance. This study had limitations; it did not evaluate survival outcomes and was 
completed using secondary data from ovarian cancer patients enrolled in a clinical trial, 
which introduces selection bias and likely represents a homogenous group. The authors 
report the study population was 90% NHW with relatively little variability in zip code 
characteristics. Our catchment area spans several counties and zip codes; thus, we 
expect to have a heterogenous group of patients to better evaluate the association 
between socioeconomic status and survival.   
2.1 Population 
The University of Kansas Cancer Center (KUCC) is the only NCI-CC in the state of 
Kansas and serves a large catchment area. KUCC’s catchment area includes the entire 
state of Kansas (105 counties) and 18 counties in Western Missouri. Of the 123 counties, 
96 are either rural or frontier counties, and include significantly underserved communities, 
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largely elderly rural NHWs, Native Americans, and immigrant Asia populations. Yet, 
KUCC is in the urban core of Kansas City that includes an established urban NHB and a 
rapidly growing Hispanic population. KUCC is between 190 and 594 miles from the 
nearest 6 current NCI-CCs. Therefore, patients travel long distances to seek care at this 
tertiary NCI-CC.  
In the state of Kansas, the incidence of ovarian cancer is similar to the national average 
at 11.4 per 100,000 and the mortality is rate is 7.1 per 100,000 [13] However, there is a 
gap in knowledge regarding the impact of racial/ethnic and geographic classifications on 
ovarian cancer survival in Kansas. Additionally, rates of the receipt of NCCN guideline 
adherent care is also unknown. At KUCC, we are uniquely positioned to investigate both 
racial/ethnic and geographic disparities in ovarian cancer because of the broad urban, 
rural and frontier populations we serve. The primary objective of this study is to determine 
the impact of race and geographic classification in women treated for ovarian cancer at 
KUCC over a 5-year period (2010-2015). We will also determine the rate of NCCN-


















Institutional Review Board approval for the study was obtained through the University of 
Kansas Medical Center. Using an innovative search discovery tool “HERON” (Healthcare 
Enterprise Repository for Ontological Narration) patients with a diagnosis of ovarian, 
fallopian tube and primary peritoneal cancer (using ICD-9 and ICD-10 codes) between 
2010-2015 were identified. Additionally, the “C3OD” Curated Clinical Cancer Outcomes 
database, the institution’s cancer registry, was also queried for ICD-O-3 codes pertaining 
to ovarian, fallopian tube and primary peritoneal cancers between 2010-2015. After 
patients in both datasets were identified, chart review was used to exclude patients with 
recurrent disease, non-epithelial histology, synchronous tumors and patients who did not 
receive any care at the institution (i.e. presented for second opinion), appendix A. Patients 
who received only chemotherapy, had reoperation for staging or primary surgical staging 
then additional care (ie. adjuvant chemotherapy) at an outside institution were 
categorized as receiving partial care at KUCC.   
Manual chart review was completed to abstract clinical characteristics including, age, 
stage at diagnosis, date of diagnosis, type of chemotherapy and number of cycles, 
presence of comorbidities at diagnosis, dates of recurrence (if any), and death (if 
deceased) of patients who met criteria. Platinum resistance was defined as recurrence 
less than 6 months following the end of chemotherapy. Operative reports were reviewed 
to determine surgical debulking status of 1) no residual disease, 2) optimal debulking (< 
1cm of residual disease) or 3) suboptimal debulking (>1cm of residual disease). Baseline 
comorbidity score was computed using Charlson Comorbidity Index (CCI) to account for 
baseline health conditions, scores for metastatic cancer was excluded since all patients 
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in the study have cancer. Receipt of stage-specific NCCN-guideline adherent care was 
determined according to the guidelines of 2008 [14]. NCCN-guideline adherent surgical 
care for advanced stage disease includes 1) laparotomy/total abdominal hysterectomy, 
removal of bilateral ovaries and fallopian tubes with comprehensive staging or 2) 
unilateral removal of ovary and fallopian tube for clinical stage 1A-1C with comprehensive 
staging if patient desires fertility 3) cytoreductive surgery if clinical stage II, III or IV or 3) 
interval cytoreduction for patients with bulky stage III/IV disease who are not surgical 
candidates. NCCN-guideline adherent chemotherapy treatment includes completion of 6 
cycles of multiagent chemotherapy including intravenous taxane and platinum agent for 
stage II-IV. For stage IA or IB, grade 1 observation was considered guideline adherent. 
For stage IA or IB, grade 2 observation or 3-6 cycles IV taxane/platinum chemotherapy 
was considered guideline adherent. For stage IA or IB grade 3 and stage IC any grade, 
3-6 cycles of intravenous taxane/platinum chemotherapy was guideline adherent. 
To evaluate the impact of racial/ethnic and geographic classification on survival outcomes 
among patients who received all their treatment for ovarian cancer at the institution, we 
collected demographic information including self-reported race and geographic distance 
to KUCC (miles). Patients were stratified by <10 miles to KUCC, 10-50 miles and greater 
than 50 miles to the institution based on previous literature [10]. Due to sample size and 
concerns for survival curve proportionality assumptions (survival curves were not 
parallel), patients were recategorized into greater than and less than 10 miles to the 
institution.  To evaluate possible confounders, insurance status was obtained, Medicaid 
and Medicare were categorized as public insurance.  Median income was estimated using 
the 2013 American Census Survey tables by matching on state, county, tract and block 
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group (or zip code if the address is a P.O. Box). Primary outcomes were overall survival 
(time from diagnosis to death) and progression free survival (time from treatment 
completion to recurrence). For patients who were known to be alive at the time of data 
collection (10/2019), time to outcome was censored at date of last clinical encounter. Date 
of death was obtained through manual chart review using our electronic health record 
system with access to integrated electronic medical records of other institutions (Epic 
Care Everywhere). Additionally, HERON and C3OD databases are integrated with the 
social security death index to provide date of death for patients who died outside of our 
health system and integrated records system.  
3.2 Statistical Methods 
Descriptive statistics were used for patient demographics (including age, race and 
geographic classification) and clinical characteristics. Chi-squared or Fisher’s exact test 
were used to assess differences between categorical variables.  Survival curves for 
overall survival and progression free survival were generated using the Kaplan-Meier 
estimate of survival probability and analyzed using the log rank test. Survival 
proportionality assumptions were examined. We conducted stratified analyses by 
geographic classification, and median income to evaluate the individual effect on 
mortality. Cox proportional hazards model were fitted for covariates and known predictors 
of poor survival including stage at diagnosis, age and cytoreductive status. Statistical 









4.1 Demographic and Clinical Factors  
A total of 329 patient met study criteria, 227 received all care for ovarian cancer at KUCC 
and 102 patients received partial care at KUCC. Of the 227 patients who received all their 
care at the institution, 51 patients lived within 10 miles and 176 lived greater than 10 miles 
from the institution (Table 1). Approximately 88% of patients were white with an estimated 
median income of $55,268. Mean age and age group distribution was similar between 
both groups. More non-white patients lived within 10 miles than greater than 10 miles 
from the institution, p =0.0007.  Most patients presented with papillary serous histology 
(%) and stage III disease (%) at diagnosis. The vast majority of patients received NCCN 
guideline adherent care (84%) and underwent optimal cytoreductive surgery (80%). 
However, more patients who lived greater than 10 miles away received optimal 
cytoreductive therapy than those who lived less than 10 miles away, 83.5% vs. 67%, 
p=0.0324. When stratified by race, non-white patients had lower rates of optimal 
cytoreduction and higher rates of not receiving surgery (Table 2). There were no other 
demographic and clinical differences by race noted. There was no difference in receipt of 
NCCN guideline adherent care by distance to the institution. However, there was a 
difference in receipt of NCCN guideline adherent care by stage (Table 3).  
4.2 Decreased overall survival among patients who live less than 10 miles to 
institution.  
Among patients who received all their ovarian cancer care at KUCC, median progression 
free survival was 26 months and median overall survival was 64 months.  There was no 
difference in progression free survival by distance to the institution (Figure 1). Patients 
who lived less than 10 miles to the institution had worse overall survival than those that 
lived greater than 10 miles away, p = 0.0137 (Figure 2). There was a 1.67 increased risk 
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of death among patients who lived less than 10 miles to the institution, 95% CI 1.10-2.52, 
p= 0.0153.  There was no difference in progression free survival by distance to the 
institution. The 5-year survival rate was 37% for patients who lived less than 10 miles to 
the institution and 57% for those who lived greater than 10 miles away.  
4.3 Comorbidities and lower estimated median income associated with increased 
risk of death in ovarian cancer patients.  
Patients with lower estimated median income had worse overall survival than patients 
with higher median income, p=0.0210 (Figure 3). There was no difference in survival by 
insurance status, data not shown. After controlling for age, non-white race, late stage 
disease at diagnosis, Charlson Comorbidity Index (CCI), lower estimate median income 
and suboptimal cytoreduction, distance less than 10 miles was not associated with an 
increased risk of death (Table 4). CCI was associated with a 1.20 increased risk of death, 
95% CI (1.021 – 1.418), p =0.0274. There was no difference in survival when stratified by 
CCI, data not shown.  Estimated median income of less than $55,268 was also associated 
with a 1.52 increased risk of death, 95% CI (1.005 – 2.292), p = 0.0473. Non-white race 






Table 1. Demographic and clinical factors by distance. 
*National Comprehensive Cancer Network (NCCN)  
#Fisher’s exact test used due to small sample size; chi-square test used otherwise.   
 Overall (%) 
n = 227  
<10 miles (%) 
n = 51  
>10 miles (%) 
n = 176 
p-value 
Age in years (mean) ± SD 60.6 ± 11.0 60.6 ± 11.1 60.6 ± 11.0 0.9999 






























Insurance status  
Private 















Median Income  
Less than $55,268 









































































































































Table 2. Demographic and clinical factors by race. 
*National Comprehensive Cancer Network (NCCN)  
#Non-white race: 18 Black, 5 Asian, 8 Latina and 6 ‘other’ 
Fisher’s exact test used due to small sample size. 
 
 
 Overall (%) 
n = 227  
White Race (%) 
n = 200  
Non-white race# (%) 
n = 27 
p-value 
Age in years (mean) ± SD 60.6 ± 11.0 60.9 ± 10.9 57.7 ± 10.9 0.1495 

















Insurance status  
Private 















Median Income  
Less than $55,268 














































































































































*Includes 19 patients that died prior to completion of treatment.  
#Fisher’s exact test. 
 
 
Table 4. Adjusted all-cause mortality. 
 *Age and CCI are continuous variables, all others categorical. 
 
  
 NCCN adherent (%) 
n = 191 
NCCN non-adherent* (%) 
n =36 
p- value# 
















Variables Hazard Ratio* 95% CI p-value 
< 10 miles to NCI-CC 1.19 0.751 – 1.902 0.4511 
Age at diagnosis 0.99 0.968 – 1.017 0.5458 
Non-white race 0.80 0.406 – 1.559 0.5048 
Late Stage (III/IV) 5.43 2.577 – 11.437 <0.001 
Charlson Comorbidity Index (CCI) 1.20 1.021 – 1.418 0.0274 
Lower Median Income <$55,268 1.52 1.005 – 2.292 0.0473 




Figure 1. Progression free survival by geographic distance.  
 














5.1 Demographic and Clinical Factors  
Of the 102 patients who received partial care at the institution, 17 (17%) received 
chemotherapy alone, 11 (11%) had reoperation for staging surgery and 75 (74%) had 
primary staging surgery alone at the institution. Like the all care cohort, 90% of patients 
were white with an estimated median income of $51,667 (Table 5). The majority of 
patients presented with papillary serous histology (70%) and late stage ovarian cancer 
(67%). 74% of patients underwent optimal cytoreductive surgery and only 9% received 
neoadjuvant chemotherapy. More than half (55%) of patients had a CCI of greater than 
2.  
5.2 Older age, higher CCI and advanced stage disease more likely to receive non-
NCCN guideline adherent care.  
Among patients who received partial ovarian cancer care at KUCC, median overall 
survival was 57 months. Most patients (81%) received NCCN guideline adherent care. 
Patients who received non-NCCN guideline adherent care were older (age >75), had 
higher CCI values and advanced stage disease at diagnosis as compared to patients who 
received NCCN guideline adherent care (Table 5). There was no difference in race, 
insurance status, histology, median income, cytoreduction status or receipt of 
neoadjuvant therapy by NCCN guideline adherent status. There was no difference in 





4.3 No difference in overall survival among patients who received all or partial care 
at NCI-CC.  
There was no difference in race, estimated median income and insurance status of 
patients who received all vs partial care at NCI-CC. However, patients who received 
partial care were more likely to live greater than 10 miles away 95% v. 78%, p <0.0001. 
Patients who received all care at KUCC had higher CCI and were more likely not to have 
had surgery (Table 6). Of the 11 patients who did not receive surgery, 4 had neoadjuvant 
chemotherapy and died prior to planned surgery, 2 had progression of disease on 
neoadjuvant chemotherapy and 7 had chemotherapy only without plan for surgery due to 
patient preference or patient being deemed not a surgical candidate.   However, there 
was no difference in receipt of NCCN guideline adherent care between groups. There 
was no difference in all-cause overall survival among patients who received all or partial 




Table 5. Demographic and clinical factors by NCCN guideline adherence. 
*National Comprehensive Cancer Network (NCCN)  




 Overall (%) 
n = 102  
NCCN* Adherent 
n = 83  
NCCN non-adherent 
n = 19 
p-value 
Age in years (mean) ± SD 61.7 ± 11.9 60.3 ± 11.6 67.9 ± 11.4 0.0159 






























Insurance status  
Private 















Median Income  
Less than $51,667 
























































































































Table 6.  Demographic and clinical factors by care received at NCI-CC. 
 Overall (%) 
n = 329  
All Care 
n = 227  
Partial Care 
n = 102 
p-value 
Age in years (mean) ± SD 62.6 ± 11.7 62.6 ± 11.7 61.7 ± 11.9 0.5364 






























Insurance status  
Private 















Median Income  
Less than $54,778 

















Distance to NCI-CC 
 < 10 miles 













































































































































Patients with newly diagnosed ovarian cancer often travel long distances to receive care. 
KUCC is between 190 and 594 miles from the nearest 6 NCI-CCs and our catchment 
area spans the entire state of Kansas and western Missouri. Thus, patients often travel 
long distances to receive care at our institution. Unlike other studies that demonstrate 
residential distance greater than 50 miles to be associated with worse outcomes, our 
study has shown that geographic proximity (<10 miles) is associated with worse overall 
survival for patients who receive all their care at our institution. 
Our NCI-CC is located in Wyandotte county, Kansas, which has the worst health 
outcomes in the state of Kansas, including the highest risk of premature death, low 
birthweight, obesity and physical inactivity [15]. Wyandotte county Kansas also has the 
highest number of uninsured residents and income inequality in the state. In prior studies, 
geographic disparities in ovarian cancer were also associated with lower socioeconomic 
status and NHB race [6]. Consistent with this finding, our study has shown that lower 
median income is associated with decreased overall survival and is a risk factor for 
mortality.  
Although race was not associated with worse overall survival, compared with white 
women, non-white women were more likely to live closer to the institution and had lower 
rates of optimal debulking. It is likely that the small percentage of non-white patients (12%) 
was not adequate to detect a difference in survival based on race. Despite this, it is 
notable that non-white patients and those who lived within 10 miles had lower rates of 
optimal debulking and higher rates of not receiving any surgical care. This result provides 
a window into potential disparities in our patients and is consistent with a previous study 
in Southern Alabama where NHB patients had lower rates of optimal debulking [16]. 
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Multiple prior studies have shown that NHB race is associated with inequity in treatment, 
including delays in chemotherapy initiation and decreased rates of surgical staging [3, 6, 
7, 17, 18]. Recently, Dilley et al. showed that NHB race was also associated with higher 
medical comorbidities and lower rates of optimal cytoreduction [19]. In that study, after 
controlling for age, stage, CCI and suboptimal cytoreduction, NHB was still associated 
with worse survival, however, they did not account for socioeconomic status. In our study, 
there was no difference in presence of comorbidities by distance to the institution or by 
race. 
After controlling for age at diagnosis, non-white race, late stage at diagnosis, presence of 
comorbidities, median income and suboptimal cytoreduction; geographic distance was 
not an independent predictor of worse overall survival. Still, given the association between 
geographic distance, median income and race, geographic distance may be a surrogate 
measure for neighborhood socioeconomic status in this cohort. A previous study in Cook 
County, Illinois has shown that neighborhood disadvantage, characterized by lack of 
economic resources, education, employment and health care, is significantly associated 
with worse ovarian cancer survival [20]. In that study, adjusting for clinical factors 
attenuated but did not completely account survival disparities, however, they did not 
include adjustments for cytoreduction status or comorbid conditions.    
NCCN guideline adherent care for ovarian cancer is a validated measure of quality cancer 
care and improved survival [21]. Geographic disparities in ovarian cancer survival have 
been associated with receipt of NCCN guideline adherent care. In California, only 45% of 
patients received NCCN guideline adherent care. In that study, geographic proximity to 
high-volume hospitals was associated with receiving NCCN guideline adherent care[9]. 
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We found that receipt of NCCN guideline adherent care was above 80% regardless 
distance to the institution or care received (all vs partial). Patients who did not receive 
NCCN guideline adherent care often had more comorbid diseases, were older, presented 
with late stage disease, were not surgical candidates or declined surgical management.  
Our NCI-CC is the only NCI-designated cancer center in the region; thus, patients often 
present to our institution for partial care and receive the rest of their care at institutions 
closer to home. This is supported by the finding that 95% of patients who received partial 
care lived greater than 10 miles from the institution and 75% of our partial care patients 
had primary staging surgery at our institution then chemotherapy at outside institutions. 
Although patients received partial care at our NCI-CC, our fellowship-trained gynecologic 
oncologists often direct cancer care in coordination with the local medical oncologist. This 
is not uncommon since greater than 70% of gynecologic oncologist practice in urban 
settings [22]. When surveyed about solutions to overcome barriers to care for patients 
who live outside of urban centers, gynecologic oncologists believed that the best solution 
was to coordinate local and centralized services [22]. For instance, patients would travel 
for high complexity components of care, such as surgery, with routine chemotherapy or 
radiation treatments being coordinated locally. Our study is the first to our knowledge to 
report that patients receive NCCN guideline adherent care at similar rates regardless of 
whether they received all or partial ovarian cancer care at an NCI-CC. Similarly, we found 
no difference in survival among patients who received all vs partial care at our institution.  
In summary, we report high rates of NCCN guideline adherent care for ovarian cancer 
and reports no difference in survival based on care (all vs partial) received at a single 
NCI-CC that serves a large catchment area. Patients who live in geographic proximity to 
31 
 
the institution have an increased risk of death associated with lower socioeconomic status 
and lower rates of optimal cytoreduction. Consistent with prior studies, advanced stage 
at diagnosis, presence of comorbidities and suboptimal cytoreduction is associated with 
an increased risk of death in this cohort. This study highlights the importance of mitigating 
disparities in survival outcomes and has potentially identified an actionable disparity in 
rates of optimal debulking.  
Strengths. 
To our knowledge, this is the first study to describe ovarian cancer survival outcomes and 
NCCN guideline adherence among women in Kansas. A strength of our analysis is that it 
was performed at a single NCI-CC with a catchment area that encompasses an entire 
understudied population—the state of Kansas which is not represented in national 
databases (i.e. SEER).  This study leverages two independent databases, HERON and 
C3OD, to ensure a complete cohort of patients treated during the study period. Complete 
chart review also allowed us to include detailed variables such as tumor cytoreduction 
status, patient comorbid conditions, physician volume, physician specialty that were often 
lacking in prior studies. 
Limitations. 
This is a retrospective study that has inherent potential for errors in reporting. The 
retrospective nature of this study also makes it impossible to control for unknown potential 
confounders or variables. Additionally, due to low numbers of non-white patients, NHB, 
Asian and Latina women were grouped into one group (non-), which does not adequately 
address racial heterogeneity.  
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To estimate median income, we used the census data from the block group of the 
patient’s residence not their actual income data. This might lead to an over or 
underestimation of median income for subjects in the study. However, there is no other 
practical way to generate income data for this type of study.  
For patients in the partial care group, we may not have complete data for ovarian cancer 
recurrence because patients may not return to our institution for treatment but will likely 
continue to receive treatment from an outside oncologist. Since our databases are 
integrated with the social security death index, we believe our overall survival rates are 
as accurate as possible.  
Considerations for Future Research. 
Our cohort consists of patients who received care at our NCI-CC, thus, it is not possible 
to determine outcomes for patients without any access to care. To determine the true 
benefit of receiving care at an NCI-CC and rates of NCCN guideline adherence in the 
catchment area, it is important to evaluate outcomes for patients who did not receive any 
care at an NCI-CC. Further studies are warranted to determine ovarian cancer outcomes 
and rates of NCCN guideline adherent care in Kansas using state-level cancer registry 
data.   
We have described potential disparities in treatment for patients who live less than 10 
miles to the institution. Disparities due to social determinants of health of patients who 
reside in Wyandotte County, Kansas may be better assessed with qualitative studies that 




One actionable factor that may contribute to disparities among our patients is receipt of 
optimal cytoreduction, it is important to be cognizant of this disparity and make all efforts 
to ensure patients have the best chance of having an optimal cytoreductive surgery. Dilley 
et al. reported that in response to finding similar results among their patients, they 
performed a quality improvement project in which providers utilized a checklist to assess 
perioperative morbidity to reinforce decisions to pursue neoadjuvant chemotherapy 
instead of cytoreduction surgery [19]. Following this intervention, they report an increase 
in their rates of optimal cytoreduction [23]. A similar intervention, following a standard 
algorithm could be implemented within our practice to mitigate disparities in optimal 
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Appendix A. Flow diagram of patients screened for inclusion criteria. 
